Cargando…

Details of the connector setting outside the V0C box.

Details of the connector setting outside the V0C box.

Detalles Bibliográficos
Autor principal:	Grossiord, Jean-Yves
Publicado:	2006
Materias:	FMD Forward Multiplicity Detector
Acceso en línea:	http://cds.cern.ch/record/1045978

Ejemplares similares

Details of the connector(3) and central element (4) setting inside the V0C box.
por: Grossiord, Jean-Yves
Publicado: (2006)

The 96 optical fibre bundles for the transfer of the light from the V0C disk to the photo-multipliers.
por: Grossiord, Jean-Yves
Publicado: (2006)

View of the inner part of the VO prototype box. The WLS fibres wrapped up in teflon strips are coupled to connectors which ensure the passage of the light outside the box and its transfer in optical fibres.
Publicado: (2004)

The V0 detector is two disks of counters in both sides of the interaction point.
por: Grossiord, Jean-Yves
Publicado: (2006)

A V0C detector prototype
Publicado: (2005)

One of the eight sectors of the V0A trigger hodoscope.
Publicado: (2005)

View of the VO prototype made of two sectors of scintillating counters. WLS fibres embedded within connectors appear in green color. Beams of optical fibres inside black sheath collect and transport the emitted light to photo-multipliers a few meters apart.
Publicado: (2004)

Two sectors of a VO prototype according to the design 2 where WLS fibres are laid along the radial edges of each scintillating element.
Publicado: (2004)

Volume 5 Editor’s Forward
por: Cripps, Allan W.
Publicado: (2016)

The space between leave and remain: archetypal positions of British parliamentarians on Brexit
por: Woollen, Constance
Publicado: (2021)

Welcome to the supplement on measurement of healthy ageing
por: Diaz, Theresa, et al.
Publicado: (2023)

Detail of connectors for PID's and ST's in the CPLEAR spectrometer
por: M. Droege
Publicado: (1991)

Extension of the Human Fibrinogen Database with Detailed Clinical Information—The αC-Connector Segment
por: Sovova, Zofie, et al.
Publicado: (2021)

Immune response to SARS-CoV-2 vaccination in relation to peripheral immune cell profiles among patients with multiple sclerosis receiving ocrelizumab
por: Räuber, Saskia, et al.
Publicado: (2022)

SARS-CoV-2 mRNA vaccinations fail to elicit humoral and cellular immune responses in patients with multiple sclerosis receiving fingolimod
por: Meyer-Arndt, Lil, et al.
Publicado: (2022)

Comparing humoral immune response to SARS‐CoV2 vaccines in people with multiple sclerosis and healthy controls: An Austrian prospective multicenter cohort study
por: Bsteh, Gabriel, et al.
Publicado: (2022)

Humoral immunity to SARS-CoV-2 mRNA vaccination in multiple sclerosis: the relevance of time since last rituximab infusion and first experience from sporadic revaccinations
por: König, Marton, et al.
Publicado: (2023)

Low protection from breakthrough SARS-CoV-2 infection and mild disease course in ocrelizumab-treated patients with multiple sclerosis after three mRNA vaccine doses
por: Novak, Frederik, et al.
Publicado: (2023)

Thinking outside the box
por: Peeraer, G.
Publicado: (2013)

Thinking Outside of the Box
por: Kalantar Motamedi, Mohammad Hosein
Publicado: (2012)

Thinking Outside the Box
por: Trevas, Sara, et al.
Publicado: (2022)

Long-term (up to 4.5 years) treatment with fingolimod in multiple sclerosis: results from the extension of the randomised TRANSFORMS study
por: Cohen, Jeffrey A, et al.
Publicado: (2016)

Disability progression in multiple sclerosis patients using early first‐line treatments
por: Lefort, Mathilde, et al.
Publicado: (2022)

Clinical autonomic nervous system laboratories in Europe: A joint survey of the European Academy of Neurology and the European Federation of Autonomic Societies
por: Habek, Mario, et al.
Publicado: (2022)

Low-dose rituximab should be used for treating MS in resource-limited settings: No
por: Mateen, Farrah J
Publicado: (2022)

Low-dose rituximab should be used for treating MS in resource-limited settings: Yes
por: Piehl, Fredrik, et al.
Publicado: (2022)

Efficacy of subcutaneous interferon β-1a on MRI outcomes in a randomised controlled trial of patients with clinically isolated syndromes
por: De Stefano, Nicola, et al.
Publicado: (2014)

Memory in multiple sclerosis is linked to glutamate concentration in grey matter regions
por: Muhlert, Nils, et al.
Publicado: (2014)

Tobacco smoking and excess mortality in multiple sclerosis: a cohort study
por: Manouchehrinia, Ali, et al.
Publicado: (2014)

Oral ponesimod in relapsing–remitting multiple sclerosis: a randomised phase II trial
por: Olsson, Tomas, et al.
Publicado: (2014)

Long-term impact of interferon beta-1b in patients with CIS: 8-year follow-up of BENEFIT
por: Edan, G, et al.
Publicado: (2014)

Efficacy and safety of natalizumab in multiple sclerosis: interim observational programme results
por: Butzkueven, Helmut, et al.
Publicado: (2014)

Changes to anti-JCV antibody levels in a Swedish national MS cohort
por: Warnke, Clemens, et al.
Publicado: (2013)

Incidence and prevalence of multiple sclerosis in the UK 1990–2010: a descriptive study in the General Practice Research Database
por: Mackenzie, I S, et al.
Publicado: (2014)

Re-evaluating the treatment of acute optic neuritis
por: Bennett, Jeffrey L, et al.
Publicado: (2015)

The grey matter correlates of impaired decision-making in multiple sclerosis
por: Muhlert, Nils, et al.
Publicado: (2015)

MRI in Leber's hereditary optic neuropathy: the relationship to multiple sclerosis
por: Matthews, Lucy, et al.
Publicado: (2015)

Establishing pathological cut-offs of brain atrophy rates in multiple sclerosis
por: De Stefano, Nicola, et al.
Publicado: (2016)

A 60-year follow-up of the incidence and prevalence of multiple sclerosis in Hordaland County, Western Norway
por: Grytten, N, et al.
Publicado: (2016)

Multiple sclerosis deep grey matter: the relation between demyelination, neurodegeneration, inflammation and iron
por: Haider, Lukas, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_np6m6od1jtv3fe3sc9sjcgff3u